A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility
Abstract
:1. Introduction
2. Results
Clinical Characteristics at Baseline | SJS | Controls | All | p (SJS/TEN vs. Controls) |
---|---|---|---|---|
Age, years | 31 (27–36) | 32 (27–36) | 32 (27–36) | 0.8 |
Viral load, log copies/mL | 4.1 (3.2–4.6) | 3.58 (2.39–4.43) | 3.72 (2.98–4.49) | 0.41 |
CD4 cell count, median cells/mm3 | 467 (326–721) | 393 (227–591) | 409 (230–634) | 0.21 |
BMI | 22.8 (21.5–25.4) | 22.8 (21.6–26.3) | 22.8 (21.6–25.9) | 0.78 |
ALT baseline U/L | 8.6 (6.9–12.8) | 10.7 (7.3–15.4) | 10.2 (7.1–15.2) | 0.28 |
AST baseline U/L | 20.5 (15.9–23.5) | 20.3 (16.9–23.6) | 20.4 (16.8–23.6) | 0.91 |
SNP | SNP Location | Cases/Controls | N | Genotypes * | p § | OR § (95% CI) | Alleles | p | OR (95% CI) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
wt | hz | var | Wildtype | Variant | ||||||||
rs76228616 G>C | Exon 2 | SJS/TEN | 27 | 19 | 7 | 1 | 0.027 | 3.6 (1.2–10.95) | 45 | 9 | 0.012 | 3.65 (1.33–10.01) |
Controls | 77 | 69 | 8 | 0 | 146 | 8 | ||||||
rs33980500 G>A | Exon 3 | SJS/TEN | 27 | 20 | 5 | 2 | 0.25 | 1.93 (0.67–5.54) | 45 | 9 | 0.12 | 2.2 (0.88–5.49) |
Controls | 78 | 66 | 11 | 1 | 143 | 13 | ||||||
rs149246847 A>C | SJS/TEN | 22 | 22 | 0 | 0 | 0.55 | ND | 44 | 0 | 0.55 | ND | |
Controls | 50 | 47 | 3 | 0 | 97 | 3 | ||||||
rs13190932 C>T | SJS/TEN | 27 | 25 | 2 | 0 | 1 | 0.81 (0.16–4.17) | 52 | 2 | 1 | 0.82 (0.16–4.07) | |
Controls | 78 | 71 | 7 | 0 | 149 | 7 | ||||||
rs113085690 T>C | Intron 6 | SJS/TEN | 27 | 27 | 0 | 0 | 1 | ND | 30 | 0 | 1 | ND |
Controls | 50 | 49 | 1 | 0 | 55 | 1 | ||||||
rs115622353 C>G | Exon 7 | SJS/TEN | 27 | 26 | 1 | 0 | 0.65 | 0.44 (0.05–4.17) | 53 | 1 | 0.66 | 0.45 (0.05–4.16) |
Controls | 50 | 46 | 4 | 0 | 96 | 4 | ||||||
rs34659678 G>A | SJS/TEN | 25 | 25 | 0 | 0 | 0.29 | ND | 50 | 0 | 0.3 | ND | |
Controls | 50 | 46 | 4 | 0 | 96 | 4 | ||||||
rs112619881 G>A | SJS/TEN | 26 | 24 | 2 | 0 | 0.49 | 0.51 (0.1–2.66) | 50 | 2 | 0.5 | 0.53 (0.11–2.7) | |
Controls | 50 | 43 | 7 | 0 | 93 | 7 | ||||||
rs2280985 T>C | Intron 9 | SJS/TEN | 27 | 25 | 2 | 0 | 1 | 0.69 (0.12–3.8) | 52 | 2 | 1 | 0.7 (0.13–3.74) |
Controls | 48 | 43 | 5 | 0 | 91 | 5 | ||||||
rs6912112 T>C | SJS/TEN | 27 | 12 | 11 | 4 | 0.54 | 1.32 (0.54–3.17) | 35 | 19 | 0.39 | 1.38 (0.72–2.67) | |
Controls | 78 | 40 | 32 | 6 | 112 | 44 | ||||||
rs138485893 T>C | Exon 10 | SJS/TEN | 27 | 27 | 0 | 0 | 0.57 | ND | 54 | 0 | 0.57 | ND |
Controls | 78 | 75 | 3 | 0 | 153 | 3 |
Variables | B | p | OR (95% CI) | R2 (Cox and Snell) |
---|---|---|---|---|
age | 0.065 | 0.142 | 1.07 (0.98–1.16) | 0.246 |
Viral load (baseline) | 0.00 | 0.311 | 1.00 | |
BMI | 0.017 | 0.815 | 1.02 (0.88–1.17) | |
CD4_50 (baseline) | 0.111 | 0.083 | 1.12 (0.99–1.27) | |
TRAF3IP2 rs76228616 | 1.479 | 0.027 | 4.39 (1.19–16.23) | |
CYP2B6 rs3745274 | 1.147 | 0.006 | 3.15 (1.38–7.19) | |
CYP2B6 rs28399499 | 1.579 | 0.011 | 4.85 (1.43–16.4) | |
HCP5 rs3099844 | 0.595 | 0.158 | 1.81 (0.79–4.14) |
CYP2B6 rs28399499 | |||||
---|---|---|---|---|---|
TT | TC + CC | ||||
SJS/TEN | Controls | SJS/TEN | Controls | ||
TRAF3IP2 rs76228616 | GG | 13 | 61 | 6 | 8 |
GC + CC | 7 | 8 | 1 | 0 |
3. Discussion
4. Experimental Section
4.1. Patients
4.2. Genotyping and Statistical Analysis
Supplementary Materials
Author Contributions
Conflicts of Interest
References
- Auquier-Dunant, A.; Mockenhaupt, M.; Naldi, L.; Correia, O.; Schröder, W.; Roujeau, J.C.; SCAR Study Group. Severe cutaneous adverse reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: Results of an international prospective study. Arch. Dermatol. 2002, 138, 1019–1024. [Google Scholar] [CrossRef] [PubMed]
- French, L.E. Toxic epidermal necrolysis and Stevens Johnson syndrome: Our current understanding. Allergol. Int. 2006, 55, 9–16. [Google Scholar] [CrossRef] [PubMed]
- Schwartz, R.A.; McDonough, P.H.; Lee, B.W. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J. Am. Acad. Dermatol. 2013, 69, 187.e1–187.e16. [Google Scholar] [PubMed]
- Warren, K.J.; Boxwell, D.E.; Kim, N.Y.; Drolet, B.A. Nevirapine-associated Stevens–Johnson syndrome. Lancet 1998, 351, 567. [Google Scholar] [CrossRef] [PubMed]
- Fagot, J.P.; Mockenhaupt, M.; Bouwes-Bavinck, J.N.; Naldi, L.; Viboud, C.; Roujeau, J.C.; EuroSCAR Study Group. Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. AIDS 2001, 15, 1843–1848. [Google Scholar] [CrossRef] [PubMed]
- Dieterich, D.T.; Robinson, P.A.; Love, J.; Stern, J.O. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 2 2004, 38 (Suppl. 2), S80–S89. [Google Scholar] [CrossRef]
- Hung, S.I.; Chung, W.H.; Jee, S.H.; Chen, W.C.; Chang, Y.T.; Lee, W.R.; Hu, S.L.; Wu, M.T.; Chen, G.S.; Wong, T.W.; et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 2006, 16, 297–306. [Google Scholar] [CrossRef] [PubMed]
- Tassaneeyakul, W.; Jantararoungtong, T.; Chen, P.; Lin, P.Y.; Tiamkao, S.; Khunarkornsiri, U.; Chucherd, P.; Konyoung, P.; Vannaprasaht, S.; Choonhakarn, C.; et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 2009, 19, 704–709. [Google Scholar] [CrossRef] [PubMed]
- Locharernkul, C.; Loplumlert, J.; Limotai, C.; Korkij, W.; Desudchit, T.; Tongkobpetch, S.; Kangwanshiratada, O.; Hirankarn, N.; Suphapeetiporn, K.; Shotelersuk, V. Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008, 49, 2087–2091. [Google Scholar] [CrossRef] [PubMed]
- Carr, D.F.; Chaponda, M.; Jorgensen, A.L.; Castro, E.C.; van Oosterhout, J.J.; Khoo, S.H.; Lalloo, D.G.; Heyderman, R.S.; Alfirevic, A.; Pirmohamed, M. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin. Infect. Dis. 2013, 56, 1330–1339. [Google Scholar] [CrossRef] [PubMed]
- Ciccacci, C.; di Fusco, D.; Marazzi, M.C.; Zimba, I.; Erba, F.; Novelli, G.; Palombi, L.; Borgiani, P.; Liotta, G. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: A pharmacogenetics study. Eur. J. Clin. Pharmacol. 2013, 69, 1909–1916. [Google Scholar] [CrossRef] [PubMed]
- Borgiani, P.; Di Fusco, D.; Erba, F.; Marazzi, M.C.; Mancinelli, S.; Novelli, G.; Palombi, L.; Ciccacci, C. HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. Eur. J. Clin. Pharmacol. 2014, 70, 275–278. [Google Scholar] [CrossRef] [PubMed]
- Lv, F.; Song, L.J.; Wang, X.H.; Qiu, F.; Li, XF. The role of Act1, a NF-κB-activating protein, in IL-6 and IL-8 levels induced by IL-17 stimulation in SW982 cells. Pharm. Biol. 2013, 51, 1444–1450. [Google Scholar] [CrossRef] [PubMed]
- May, M.J. IL-17R signaling: New players get in on the Act1. Nat. Immunol. 2011, 12, 813–815. [Google Scholar] [CrossRef] [PubMed]
- Venkatesan, B.; Valente, A.J.; Das, N.A.; Carpenter, A.J.; Yoshida, T.; Delafontaine, J.L.; Siebenlist, U.; Chandrasekar, B. CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction. Cell Signal. 2013, 25, 359–371. [Google Scholar] [CrossRef] [PubMed]
- Zhong, B.; Liu, X.; Wang, X.; Chang, S.H.; Liu, X.; Wang, A.; Reynolds, J.M.; Dong, C. Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nat. Immunol. 2012, 13, 1110–1117. [Google Scholar] [CrossRef] [PubMed]
- Genetic Analysis of Psoriasis Consortium and the Wellcome Trust Case Control Consortium 2. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 2010, 42, 985–990. [Google Scholar]
- Ellinghaus, E.; Ellinghaus, D.; Stuart, P.E.; Nair, R.P.; Debrus, S.; Raelson, J.V.; Belouchi, M.; Fournier, H.; Reinhard, C.; Ding, J.; et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 2010, 42, 991–995. [Google Scholar] [CrossRef] [PubMed]
- Hüffmeier, U.; Uebe, S.; Ekici, A.B.; Bowes, J.; Giardina, E.; Korendowych, E.; Juneblad, K.; Apel, M.; McManus, R.; Ho, P.; et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 2010, 42, 996–999. [Google Scholar] [CrossRef] [PubMed]
- Ciccacci, C.; Biancone, L.; Di Fusco, D.; Ranieri, M.; Condino, G.; Giardina, E.; Onali, S.; Lepre, T.; Pallone, F.; Novelli, G.; et al. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease. J. Crohns Colitis 2013, 7, 44–52. [Google Scholar] [CrossRef] [PubMed]
- Perricone, C.; Ciccacci, C.; Ceccarelli, F.; di Fusco, D.; Spinelli, F.R.; Cipriano, E.; Novelli, G.; Valesini, G.; Conti, F.; Borgiani, P. TRAF3IP2 gene and systemic lupus erythematosus: Association with disease susceptibility and pericarditis development. Immunogenetics 2013, 65, 703–709. [Google Scholar] [CrossRef] [PubMed]
- Genin, E.; Chen, D.P.; Hung, S.I.; Sekula, P.; Schumacher, M.; Chang, P.Y.; Tsai, S.H.; Wu, T.L.; Bellón, T.; Tamouza, R.; et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: An international study and meta-analysis. Pharmacogenomics J. 2014, 14, 281–288. [Google Scholar] [CrossRef] [PubMed]
- Tohkin, M.; Kaniwa, N.; Saito, Y.; Sugiyama, E.; Kurose, K.; Nishikawa, J.; Hasegawa, R.; Aihara, M.; Matsunaga, K.; Abe, M.; et al. A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013, 13, 60–69. [Google Scholar] [CrossRef] [PubMed]
- Excoffier, L.; Lischer, H.E.L. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 2010, 10, 564–567. [Google Scholar] [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ciccacci, C.; Rufini, S.; Mancinelli, S.; Buonomo, E.; Giardina, E.; Scarcella, P.; Marazzi, M.C.; Novelli, G.; Palombi, L.; Borgiani, P. A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility. Int. J. Mol. Sci. 2015, 16, 5830-5838. https://doi.org/10.3390/ijms16035830
Ciccacci C, Rufini S, Mancinelli S, Buonomo E, Giardina E, Scarcella P, Marazzi MC, Novelli G, Palombi L, Borgiani P. A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility. International Journal of Molecular Sciences. 2015; 16(3):5830-5838. https://doi.org/10.3390/ijms16035830
Chicago/Turabian StyleCiccacci, Cinzia, Sara Rufini, Sandro Mancinelli, Ersilia Buonomo, Emiliano Giardina, Paola Scarcella, Maria C. Marazzi, Giuseppe Novelli, Leonardo Palombi, and Paola Borgiani. 2015. "A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility" International Journal of Molecular Sciences 16, no. 3: 5830-5838. https://doi.org/10.3390/ijms16035830